tiprankstipranks
Advertisement
Advertisement

ATAI Stock Latest News

Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
The FlyPsychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
7h ago
ATAI
CMND
AtaiBeckley initiated with a Buy at Deutsche Bank
PremiumThe Fly
AtaiBeckley initiated with a Buy at Deutsche Bank
6d ago
ATAI
AtaiBeckley initiated with a Buy at Deutsche Bank
PremiumThe Fly
AtaiBeckley initiated with a Buy at Deutsche Bank
7d ago
ATAI
Psychedelic: Compass Pathways, NRx Pharma report earnings results
PremiumThe Fly
Psychedelic: Compass Pathways, NRx Pharma report earnings results
7d ago
ATAI
CMPS
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9d ago
ATAI
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
PremiumThe FlyPsychedelic: AtaiBeckley reports publication of BPL-003 study results
14d ago
ATAI
CMND
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating
Premium
Ratings
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating
15d ago
ATAI
Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price
Premium
Ratings
Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price
16d ago
ATAI
Atai Beckley announces publication of Phase 2a BPL-003 study results
PremiumThe Fly
Atai Beckley announces publication of Phase 2a BPL-003 study results
16d ago
ATAI
Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
PremiumThe Fly
Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
21d ago
ATAI
CMND
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting
PremiumThe Fly
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting
23d ago
ATAI
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
PremiumRatings
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
24d ago
ATAI
Atai Beckley reports Q4 EPS ($1.73) vs. (24c) last year
PremiumThe FlyAtai Beckley reports Q4 EPS ($1.73) vs. (24c) last year
27d ago
ATAI
Atai Beckley sees cash runway into 2029
Premium
The Fly
Atai Beckley sees cash runway into 2029
27d ago
ATAI
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
Premium
The Fly
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
28d ago
PBM
ATAI
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program
PremiumThe Fly
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program
1M ago
ATAI
Cathie Wood Leverages Baidu’s Post-Earnings Dip, Sells PagerDuty
PremiumMarket News
Cathie Wood Leverages Baidu’s Post-Earnings Dip, Sells PagerDuty
1M ago
PD
ARKK
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial
PremiumThe Fly
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial
1M ago
PFE
ABBV
Buy Rating on ATAI Life Sciences Driven by Promising Phase 2a EMP-01 Efficacy and Differentiated Dosing in Social Anxiety Disorder
PremiumRatings
Buy Rating on ATAI Life Sciences Driven by Promising Phase 2a EMP-01 Efficacy and Differentiated Dosing in Social Anxiety Disorder
1M ago
ATAI
Atai Beckley says EMP-01 met primary safety objectivein Phase 2a trial
PremiumThe FlyAtai Beckley says EMP-01 met primary safety objectivein Phase 2a trial
1M ago
ATAI
Psychedelic: Exclusive talk with nonprofit organization MAPS
Premium
The Fly
Psychedelic: Exclusive talk with nonprofit organization MAPS
1M ago
ATAI
CMND
Atai Beckley appoints Faerm as Chief Financial Officer
Premium
The Fly
Atai Beckley appoints Faerm as Chief Financial Officer
1M ago
ATAI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >